A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.

In January 2018, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.

Pfizer Inc. signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.